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Abstract 
I consider mitochondrial medicine a tentative designation for an area within clinical medicine still to be delineated. Its development 
extends over a period of 35 years, from its discovery in 1959 [1]. Progress bad been gradual until recent years when it has become 
explosive in nature with extensions in many different directions. My presentation is an effort to illustrate this evolution with emphasis on 
especially important observations which by leaps advanced the area. We are fortunate to have here several of the distinguished 
investigators, who have contributed so much to those advances. They will share with us their deep knowledge in different aspects of 
mitochondrial medicine, what is known, what remains to be elucidated, and what the problems are to be encountered in that elucidation. 
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1. The first mitochondrial disorder (1959-1962): Luft's 
disease 
The first report of the involvement of mitochondria in 
human pathology was described as "a  breakthrough in 
human chemical pathology" by Albert Lehninger in 1964 
in his book 'The Mitochondrion'. It was not only the first 
study ever on isolated human mitochondria but also on a 
disordered function of a cell organelle in man [2]. Our 
patient was a woman experiencing enormous perspiration, 
extremely high caloric intake, thinness and asthenia. The 
dominant laboratory finding was an oxygen uptake (BMR) 
of about + 200%, but with normal thyroid function. Bio- 
chemical studies of skeletal muscle mitochondria, with 
available techniques adapted for human skeletal muscle, 
demonstrated a nearly maximal rate of respiration in the 
presence of substrate alone without addition of ADP + Pi, 
but an almost normal phosphorylating efficiency in their 
presence. The mitochondria exhibited high ATPase activ- 
ity, which was only slightly stimulated by 2,4-dinitro- 
phenol, a known uncoupler of respiration from phoshoryla- 
tion. The mitochondria were also insensitive to oligomycin, 
a specific inhibitor of mitochondrial ATP synthesis. 
These features of loose-coupled respiration accounted 
for all the symptoms of the patient. At the time, the 
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observations were explained as a 'energy leak' above the 
level of the phosphorylating system. Such a proposal was 
supported some 10 years later by the observation of an 
energy dissipating futile cycle of Ca 2÷ uptake and release 
in a second patient with this disease [3]. Other remarkable 
findings in our patient were a high level of cytochrome 
oxidase, a relatively low level of coenzyme Q, and a high 
content of RNA in muscle homogenate. Electron mi- 
croscopy of the mitochondria revealed striking structural 
abnormalities including accumulations of mitochondria of 
highly variable size in the perinuclear region of the muscle 
cells and vast paracrystalline inclusions, possibly com- 
prised of lipofuscin granules. No uncoupling agent was 
found in muscle homogenate. 
Several explanations for the loose-coupling were tested 
at the time and suggested later, e.g., a short circuit of the 
flow of protons in the inner membranes partly inhibiting 
ATP production but preserving electron transport; or en- 
hanced proliferation of mitochondria with the formation of 
a component, necessary for maintaining tight-coupling be- 
tween respiration and phosphorylation, having failed to 
keep pace with the proliferation. Coenzyme Q might be a 
candidate for this component since, in our patient, its level 
was decreased relative to cytochrome oxidase. 
2. Reopening of the field of mitochondrial diseases 
At the beginning of the 1970s, aberrations of the respira- 
tory chain, with or without structurally abnormal mito- 
chondria of the type observed in Luft's disease, were 
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realized also to occur in certain other myopathies not 
associated with elevated oxygen consumption [4]. In 1970, 
Spiro et al. [5] identified a respiratory chain deficiency in a 
disease characterized by dementia, cerebellar ataxia and 
proximal muscular weakness. In the disease there are 
increased mitochondria nd a decrease in the level of 
cytochrome b in muscle. Next, Blass et al. [6] described a
defect of the pyruvate dehydrogenase complex in muscle 
and fibroblasts from a boy with episodes of ataxia, 
dysarthria nd choreoathetosis but with morphologically 
normal mitochondria. In 1972, French et al. [7] reported a
deficiency of cytochrome c oxidase in brain, liver and 
muscle mitochondria from an infant with trichopoliodys- 
trophy (Menke's syndrome). In the following year, the first 
examples were reported of myopathies due to isolated 
deficiencies of muscle carnitine [8] and carnitine palmitoyl 
transferase [9]. 
These additional clinical discoveries were the starting 
point for a more rapid expansion of the field of mitochon- 
drial pathophysiology. By 1988, Scholte's comprehensive 
review of the biochemical basis of mitochondrial diseases 
classified a total of more than 120 entities [10]. All were 
based on alterations in mitochondrial biochemistry. 
From Scholte's and subsequent reviews several basic 
principles in mitochondrial pathology emerged. First, some 
mitochondrial diseases affect only one tissue, most often 
skeletal muscle, but also brain, liver, heart, kidneys or 
endocrine glands. Other organs may be involved secondar- 
ily. The disease may originate as a specific defect in 
mitochondrial function, but a variety of genetic and envi- 
ronmental factors may contribute to the phenotype. 
Despite the diversity of clinical phenomena nd mito- 
chondrial pathology, seven syndromes have been particu- 
larly important in advancing our understanding of mito- 
chondrial medicine. 
Kearns-Sayre Syndrome (KSS) with ophthalmoplegia, 
retinal pigmental degeneration, sometimes heart block, 
ataxia, hyperparathyroidism and short stature. 
Myoclonus Epilepsy and Ragged Red Fibers syndrome 
(MERRF) with intense myoclonus, epilepsy, progressive 
ataxia, muscle weakness and wasting, deafness and demen- 
tia. 
Leber's Hereditary Optic Neuropathy (LHON) with 
blindness, at times movement disorders and encephalomy- 
opathy, ECG abnormalities and retinal microangiopathy. 
Mitochondrial myopathy, Encephalopathy, Lactic Aci- 
dosis and Stroke-like episodes (MELAS) with episodic 
vomiting, lactic acidosis, and myopathy with ragged red 
fibers, sometimes dementia, generalized seizures, deafness 
and short stature. 
Leigh's Disease or subacute necrotizing encephalomy- 
opathy - with respiratory abnormalities, weak cry, im- 
paired feeding, impaired vision and hearing, ataxia, weak- 
ness and hypotension. 
Chronic Progressive External Ophthalmoplegia (CPEO) 
and mitochondrial myopathy - with symptoms imilar to 
those in KSS but also ocular myopathy, retinitis pigmen- 
tosa and central nervous ystem (CNS) dysfunction. 
Alper's Syndrome or progressive infantile poliodystro- 
phy - with seizures, dementia, spasticity, blindness and 
liver dysfunction accompanied by specific cerebral degen- 
eration. 
The clinical expressions of these and other mitochon- 
drial syndromes may vary considerably. Overlapping be- 
tween the syndromes i common and may make diagnosis 
difficult. Clearly, tissues with a high demand for ATP and 
oxidative turnover are preferentially affected in different 
combinations. In some syndromes, endocrine glands are 
involved with signs of diabetes, hypoparathyroidism, 
stunted growth, etc. Inherited factors are present in some, 
if not all of these syndromes. Maternal inheritance is well 
established in MERRF and LHON. 
A common feature in this novel group of inborn 
metabolic errors is the involvement of specific enzymes in 
the pathway of aerobic energy production in the mito- 
chondria. Thus, a defect in coenzyme Q has been observed 
in KSS; reduced activities of respiratory complexes I and 
IV in MERRF; in complex I in LHON; in complex I and 
cytochrome c oxidase in MELAS; in cytochrome c oxi- 
dase in Leigh's syndrome. 
3. The discovery of specific mitochondrial DNA (1963- 
1964) 
That DNA is present in mitochondria (mtDNA) was 
first clearly shown in 1963 by Nass and Nass [11] who 
demonstrated morphologically that the mitochondria of 
chick embryos contained threadlike structures that could 
be digested by DNAse. Biochemical evidence that these 
structures were DNA was provided by Schatz et al. [12] 
who isolated DNA from purified yeast mitochondria. By 
1981 the complete sequence of human mtDNA had been 
elucidated [13]. Some fascinating features of mtDNA were 
observed. One of importance for clinical medicine is that it 
undergoes mutations 5-10-times faster than nuclear DNA 
[14], since there is a lack of histone proteins to protect 
mtDNA [15], and the mitochondria re not efficient in 
repairing DNA damage. About 90% of oxygen in the cell 
is consumed by mitochondria nd, as a result, there is 
extensive oxidative damage to mtDNA [ 16]. 
4. Association of eneephalomyopathies with mtDNA 
changes (1988) 
In 1988, another breakthrough in mitochondrial patho- 
physiology occurred with the report of an association of 
different sporadic human encephalomyopathies with large 
deletions of mtDNA [ 17], and a G to A transition mutation 
at nucleotide pair 11778 in the mtDNA of patients with 
LHON [18]. A constant feature in LHON has been the 
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coexistence of mutant and wild-type mtDNA (hetero- 
plasmy). Following these reports, other clinical syndromes 
were soon linked to specific mutations, deletions and 
duplications of mtDNA, impairing protein synthesis of the 
mitochondrial subunits of the respiratory chain complexes: 
e.g., point mutations of the tRNA Ly~ gene in the MERRF 
syndrome [19] and a point mutation of the tRNA Leu~uvR) 
gene in MELAS [20]. Most of the 'classical' mitochondrial 
disorders have since been submitted to detailed studies 
(reviews: [21-24]). A special feature of these tRNA muta- 
tions is that they have indistinguishable consequences at
the biochemical evel, producing partial defects in the 
mtDNA-dependent respiratory complexes. In 50% of pa- 
tients with sporadic adult-onset CPEO with ragged red 
fibers, large scale deletions ranging from 1.3 to 7.6 kb 
[25-28], or duplications [29] were observed, and in nearly 
100% of patients with KSS. No other mitochondrial en- 
cephalomyopathies had deletions. 
Variation in the ratio of wild to mutant mtDNA in 
different issues probably explains the tissue specificity of 
the mitochondrial myopathies [30]. Similarly, alterations in 
the tissue distribution of the proportion of mutant mtDNA 
with time may explain some of the age dependency. 
However, disturbances in interactions between ucleus and 
mitochondria were recently reported in families with a 
CPEO-like syndrome with autosomal dominant inheritance 
(review: [24]). This autosomal dominant disease implied 
mutation in a nucleus-encoded gene. The abnormal product 
of this nuclear gene was supposed to interact with mtDNA 
to cause multiple lesions in the molecule. This area has 
been enriched by several reports [30-33] which suggest 
new studies of possible interference with mtDNA or its 
products by nuclear gene products. These studies could 
lead to a better understanding of the pathogenesis of 
mitochondrial malfunction. 
5. Free radicals, oxidative damage and antioxidants 
Essential for the discussion of mitochondrial pathophys- 
iology are the oxidative processes in the mitochondria nd 
the consequences of abnormalities in these processes. The 
chemical oxidants - 0 2 • and OH. - with unpaired 
electrons and reactive properties, so-called free radicals, 
are normal products of the oxidative processes. They may 
be harmful when produced in increased amounts and not 
neutralized by the normally occurring antioxidants. Then 
leakage may lead to damage of membrane lipids, DNA, 
proteins and other macromolecules. 
The common sources of radicals are well known: en- 
dogenous contributors uch as destruction of cells during 
chronic infections [34], degradation of fatty acids and other 
molecules [35], processes acting as defense mechanisms 
etc; exogenous contributors such as cigarette smoke, prod- 
ucts from normal food intake [36,37], etc. Important for the 
balance of oxidation/antioxidation are the natural 
lipophilic and hydrophobic antioxidants. Coenzyme Q and 
vitamin E in reduced form as antioxidants have gained 
enormous attention during the last few years. This is 
especially relevant for coenzyme Q located as it is in the 
electron transport system by linking complexes I and III of 
the respiratory chain. In its reduced form it serves as an 
antioxidant, preventing lipid peroxidation in biological 
membranes and low density lipoproteins (LDL) and, 
thereby, plays an active role in cellular defense against 
oxidative damage. Therefore, a relative deficiency of coen- 
zyme Q, regardless of its origin, may be an important 
factor in the development of mitochondrial disorders. 
Hence, coenzyme Q has been given to an escalating num- 
ber of patients uffering from mitochondrial diseases, but 
also to a massive number of patients with diseases which 
as yet cannot be classified as belonging to this group. 
6. The ageing process and the mitochondria 
Findings have been interpreted to favor the idea that 
ageing involves oxygen radicals at some stage in its devel- 
opment. It has been proposed that mutations of mtDNA 
and changes in cellular bioenergetics contribute in some 
way to the ageing process and to the development of 
degenerative diseases. Thus, the capacity for oxidative 
phosphorylation declines with age [22] due to defective 
accumulation of mtDNA or nuclear DNA, or both. ATP 
production can decline below a level critical for the func- 
tion of the cell. There is evidence that the 'normal' ageing 
process is accompanied by damage to molecules, including 
mtDNA, and that such damage accumulates with age 
[38-41]. A 5 kb common deletion of mtDNA has been 
found to accumulate with age in human brain and skeletal 
muscle [42]. Furthermore, diseases associated with alter- 
ations in mtDNA progress with age, and this progression is
associated with an increasing proportion of deleted 
molecules. In heart muscle, mtDNA deletions - especially 
a 3.6 kb deletion - have been shown to accumulate after 
35 years of age [43-45], as has a 3 kb deletion in skeletal 
muscle [46]. In addition, the concentration of messenger 
and ribosomal mtRNA declined with age in rat brain and 
heart [47], and was associated with a 50% decrease in 
transcription rate [48]. In ischemic hearts, hypoxemic inhi- 
bition of oxidative phosphorylation was accompanied by 
an increase in mtDNA damage [49]. 
As a sign of the ageing process, the number of cy- 
tochrome c oxidase negative skeletal and heart muscle 
fibers increased with age [50,51], and enzyme activities of 
complexes I and IV declined progressively with age in 
human skeletal muscle and liver [52,53]. In addition, evi- 
dence has been presented for age-related changes in coen- 
zyme Q levels in several tissues: by Beyer et al. [54] in 
rats, and in humans by Kal6n et al. [55]. The latter authors, 
found an increase in dolichol paralleling an age-related 
decrease in reduced coenzyme Q 
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While more studies are needed, these data seem to favor 
the idea that aging may be associated with a disturbed 
balance between oxidative and antioxidative forces, lead- 
ing to a decline in oxidative phosphorylation below some 
'organ-specific threshold' and to mtDNA damage. A mor- 
phologic consequence ould be the age-related increase in 
lipofuscin granules, also termed 'age pigments' [56]. 
7. Age-related degenerative diseases 
In a search for diseases possibly connected with defects 
in oxidative phosphorylation and with alterations in 
mtDNA, it seems appropriate to look at tissues that are 
critically dependent on a large supply of ATP for their 
specific functions, e.g., CNS, heart and skeletal muscle, 
kidney, liver, retina and pancreatic islets. Such studies 
have opened a new area within the field of mitochondrial 
diseases. 
Oxidative stress has also been implicated in some neu- 
rodegenerative disorders, such as Parkinson's disease, 
amyotrophic lateral sclerosis, Huntington's disease and 
Alzheimer's disease. In all these conditions, deleted or 
mutated mtDNA and alterations on the complexes of the 
respiratory chain have been implicated. On the whole, it 
may be said that oxidative stress seems to represent one 
possible pathway leading to neuronal degeneration i a 
manner consistent with the course and pathology of some 
degenerative diseases of the CNS. Furthermore, other 
pathologic processes may be primary events enhancing the 
vulnerability of the CNS. These and other observations and 
views demonstrate the gaps in our knowledge of the 
specific metabolic processes that may promote oxidative 
stress at the neuronal level. Filling these gaps may lead to 
strategies for blocking pathways involved in neuronal de- 
generation. 
7.3. Diabetes mellitus 
7.1. The cardiovascular system 
mtDNA deletions and depressed activities of oxidative 
phosphorylation enzymes in ageing heart muscles could 
pave the way for a disturbed balance of oxidation/anti- 
oxidation with many consequences. These could include 
the appearance of atherosclerotic plaques and progression 
of myocardial diseases including dilated cardiomyopathies 
and ischemic ardiovascular syndromes. Major efforts have 
been made (1) to measure the levels of antioxidants in 
such groups of patients which have been found to be 
decreased, and (2) to treat them with large doses of 
antioxidants, mainly coenzyme Q. The latter appears to be 
an important anti-risk factor in such conditions. The find- 
ings to date, no matter how seemingly positive, must be 
considered preliminary. 
7.2. The central nervous system 
The central nervous system derives its energy almost 
exclusively from oxidative phosphorylation, and thus con- 
sumes a large amount of oxygen. Any disturbance in the 
equilibrium between oxidation and antioxidation i  CNS 
tissues could disrupt the efficiency of electron transport. 
This could hamper ATP availability to cellular functions in 
the CNS involving ion channels and pumps, exocytosis 
and various phosphorylation processes. 
In addition, processes leading to oxidative stress in the 
CNS may involve excitatory neurotransmitters, mainly glu- 
tamate [57]. These may lead to neuronal degeneration 
[58,59], possibly via processes leading to an imbalance in 
oxidation/antioxidation (sustained oxidative stress). This 
in turn, could be accompanied by cumulative damage to 
DNA, protein and lipids. The results would be especially 
harmful if for some reason, antioxidant defenses are com- 
promised as during ageing. 
NIDDM (non-insulin dependent diabetes mellitus) is an 
age-related disease, which also exhibits features of a de- 
generative disorder. The two main tissues involved, the 
pancreatic islets (concerning insulin release) and skeletal 
muscle (concerning insulin sensitivity), are both highly 
reliant on oxygen. Is there a place for the mitochondria n
the development of NIDDM? It is unlikely that common 
NIDDM comprising 90% of the diabetic population has its 
origin in specific mutations of mtDNA. However, an age- 
related decline in the capacity for oxidative phosphoryla- 
tion and its consequences could play as significant a role 
in its pathophysiology as obesity and a sedentary life-style. 
Various diabetogenic agents could operate by attacking 
the unprotected mitochondrial genome, leading to oxida- 
tive stress [60], e.g., interleukin-1/3, interferon-y, tumor 
necrosis factor-a, alloxan and streptozotocin ([61], review: 
[62]). The action of some of these agents could be inhib- 
ited by antioxidants in animal models [60,63-65] as well 
as in humans [66]. Such observations led Okamoto [67] to 
suggest hat diabetogenic agents induce breaks of mtDNA 
in islets, ultimately followed by death of/3-cells. Universal 
applicability of this hypothesis has been questioned [68]. 
Gerbitz has developed this theme further by implying an 
involvement of the mitochondrial genome in the develop- 
ment of IDDM (insulin-dependent diabetes mellitus) [62]. 
There is already some clinical evidence for the involve- 
ment of mtDNA in the development of diabetes. Patients 
with KSS and CPEO have an incidence of diabetes everal 
times higher than in the general population [69-71]. The 
earlier the onset of mitochondrial myopathy in these condi- 
tions, the more frequent was its association with IDDM 
[72]. Also MELAS and other mitochondrial cytopathies are 
occasionally associated with diabetes [73] and with a point 
mutation of mtDNA [74]. This makes it likely that alter- 
ations of mtDNA of the /3-cells may contribute to the 
development of diabetes. 
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Recently, a systemic 10.4 kb mtDNA deletion was 
reported in a pedigree with maternally transmitted iabetes 
and sensory-neural deafness [75]. Subsequently an A to G 
transition at nucleotide pair np 3243, a conserved position 
in the mitochondrial gene for tRNA Leu(UUR~, also was 
reported in families with diabetes [76-78]. This mutation 
leads to impairment of mitochondrial transcription termina- 
tion, which causes defects in mitochondrial protein synthe- 
sis [79]. A similar mutation was found in insulin antibody 
positive subjects, initially diagnosed as NIDDM, who pro- 
gressed to IDDM [80]. The positivity may follow /3-cell 
damage due to a mutation of mtDNA, or /3-cells with the 
mutation could be susceptible to autoimmune destruction. 
The mutation may be connected with a variable and pro- 
gressive decrease in insulin secretory capacity. 
8. Therapeutic aspects 
Understanding the mechanisms behind the development 
of mitochondrial diseases offers strategies for attempts at 
their treatment. Possibilities are supplementation of cofac- 
tots in the respiratory chain, addition of oxidizable sub- 
strates, and prevention of oxygen radical damage to the 
mitochondria. Under normal conditions, harm from free 
radicals is prevented by intrinsic defense mechanisms. This 
may not be so, when free radical synthesis increases, or the 
regeneration of natural protective antioxidants is insuffi- 
cient. 
Favorable results with antioxidants, 'redox therapy', 
have been reported in a number of patients with 'classical' 
mitochondrial diseases, mainly KSS. Coenzyme Q has 
occupied a special place in these attempts. Coenzyme Q 
has also been used in attempts to normalize oxidation/an- 
tioxidation abnormalities in age-related diseases. While 
there are a number of favorable reports, additional studies 
are essential to establish its possible role in therapy. 
9. Conclusions 
We can anticipate expansion of the field of mitochon- 
drial medicine in several directions. First, into some age- 
related diseases so far not approached; second, into areas 
connected with new concepts in mitochondrial biochem- 
istry and physiology, for example protein transport via the 
mitochondrial membrane. Of great interest are in depth- 
studies aiming at a better understanding of the processes 
underlying the mitochondrial defects, and well controlled 
studies on the place of nutritional supplements and replace- 
ment therapy with suitable redox compounds in the 
amelioration of disorders due to deficiencies in mitochon- 
drial bioenergetics. In this context, this symposium is most 
welcome for all of us .  
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